Potential use of humanized antibodies in the treatment of breast cancer.

Details

Serval ID
serval:BIB_CDAE852219E8
Type
Article: article from journal or magazin.
Collection
Publications
Title
Potential use of humanized antibodies in the treatment of breast cancer.
Journal
Expert review of anticancer therapy
Author(s)
Schaefer N.G., Pestalozzi B.C., Knuth A., Renner C.
ISSN
1744-8328 (Electronic)
ISSN-L
1473-7140
Publication state
Published
Issued date
07/2006
Peer-reviewed
Oui
Volume
6
Number
7
Pages
1065-1074
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
With the growing knowledge of key cellular pathways in tumor induction and evolution, targeted therapies make up an increasing proportion of new drugs entering clinical testing. In the treatment of breast cancer, humanized antibodies have become a major option. The humanized monoclonal antibody trastuzumab (Herceptin); Genentech, Inc., CA, USA) for HER2-overexpressing, metastatic breast cancer, represents a successful agent associated with impressive survival benefits when combined with chemotherapy. Based on impressive results, trastuzumab will become a standard in the adjuvant treatment of HER2-overexpressing breast cancer. The role of trastuzumab in the neoadjuvant setting is promising, but must be further evaluated in large prospective, randomized trials. However, there is still a large proportion of patients overexpressing HER2 that do not respond to trastuzumab. Regarding this patient cohort, the optimal combination of trastuzumab with other agents needs further evaluation. In breast cancer lacking HER2 amplification, the role of the new antibody pertuzumab remains to be defined. The role of antibodies interfering with angiogenesis, tumor stroma or glycoproteins is of a preliminary nature and warrants further investigation. Here, an overview of humanized antibodies in human breast cancer is provided, with emphasis on the recent advances and future prospects in treating malignant breast cancer.
Keywords
Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Breast Neoplasms/immunology, Breast Neoplasms/therapy, Clinical Trials as Topic, Female, Gene Amplification, Humans, Immunotherapy/methods, Immunotoxins/therapeutic use, Receptor, ErbB-2/genetics, Receptor, ErbB-2/physiology, Signal Transduction, Survival Analysis, Trastuzumab
Pubmed
Web of science
Create date
07/12/2017 12:27
Last modification date
21/08/2019 5:36
Usage data